Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Plasma-derived coagulation factor concentrates, prepared using traditional manufacturing processes, have transmitted viral diseases, especially AIDS, hepatitis B and hepatitis C to patients. To date, more extensive selection of blood donors, improved screening procedures of each plasma donation for direct and indirect viral markers, and newly developed virucidal procedures, especially pasteurization and solvent-detergent, together with extraction technologies of plasma proteins based on high-resolution chromatographic separations, have diminished considerably the risks of transmitting these pathogenic agents. To ensure safety, each production process must be carefully validated, following a rigorous scientific approach to assess its ability to inactivate or eliminate viruses. In addition, Good Manufacturing Practices must avoid any variation from these validated viral inactivation processes and must eliminate risks of potential downstream contamination of purified plasma fractions following viral inactivation or elimination steps. Other side-effects associated with conventional low-purity preparations, such as acute haemolytic anemia due to contamination by isohaemagglutinins, or immunosuppression possibly due to an overload in fibrinogen and immunoglobulins, have not been reported following infusion of highly purified coagulation factor concentrates. Present state-of-the-art virus inactivation and protein-purification technologies have significantly improved the safety of plasma coagulation factor concentrates.

Original languageEnglish
Pages (from-to)91-100
Number of pages10
JournalBiologicals
Volume20
Issue number2
DOIs
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

Blood Coagulation Factors
Virus Inactivation
Coagulation
Plasmas
Safety
Viruses
Contamination
Pasteurization
Technology
Donor Selection
Hemolytic Anemia
Hemagglutinins
Proteins
Virus Diseases
Hepatitis C
Blood Donors
Hepatitis B
Detergents
Immunosuppression
Fibrinogen

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Applied Microbiology and Biotechnology
  • Pharmacology
  • Immunology
  • Microbiology
  • Infectious Diseases

Cite this

Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. / Burnouf, Thierry.

In: Biologicals, Vol. 20, No. 2, 1992, p. 91-100.

Research output: Contribution to journalReview article

@article{104052fe922c49f29a76b5cdd6b1be61,
title = "Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates",
abstract = "Plasma-derived coagulation factor concentrates, prepared using traditional manufacturing processes, have transmitted viral diseases, especially AIDS, hepatitis B and hepatitis C to patients. To date, more extensive selection of blood donors, improved screening procedures of each plasma donation for direct and indirect viral markers, and newly developed virucidal procedures, especially pasteurization and solvent-detergent, together with extraction technologies of plasma proteins based on high-resolution chromatographic separations, have diminished considerably the risks of transmitting these pathogenic agents. To ensure safety, each production process must be carefully validated, following a rigorous scientific approach to assess its ability to inactivate or eliminate viruses. In addition, Good Manufacturing Practices must avoid any variation from these validated viral inactivation processes and must eliminate risks of potential downstream contamination of purified plasma fractions following viral inactivation or elimination steps. Other side-effects associated with conventional low-purity preparations, such as acute haemolytic anemia due to contamination by isohaemagglutinins, or immunosuppression possibly due to an overload in fibrinogen and immunoglobulins, have not been reported following infusion of highly purified coagulation factor concentrates. Present state-of-the-art virus inactivation and protein-purification technologies have significantly improved the safety of plasma coagulation factor concentrates.",
author = "Thierry Burnouf",
year = "1992",
doi = "10.1016/S1045-1056(05)80056-9",
language = "English",
volume = "20",
pages = "91--100",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates

AU - Burnouf, Thierry

PY - 1992

Y1 - 1992

N2 - Plasma-derived coagulation factor concentrates, prepared using traditional manufacturing processes, have transmitted viral diseases, especially AIDS, hepatitis B and hepatitis C to patients. To date, more extensive selection of blood donors, improved screening procedures of each plasma donation for direct and indirect viral markers, and newly developed virucidal procedures, especially pasteurization and solvent-detergent, together with extraction technologies of plasma proteins based on high-resolution chromatographic separations, have diminished considerably the risks of transmitting these pathogenic agents. To ensure safety, each production process must be carefully validated, following a rigorous scientific approach to assess its ability to inactivate or eliminate viruses. In addition, Good Manufacturing Practices must avoid any variation from these validated viral inactivation processes and must eliminate risks of potential downstream contamination of purified plasma fractions following viral inactivation or elimination steps. Other side-effects associated with conventional low-purity preparations, such as acute haemolytic anemia due to contamination by isohaemagglutinins, or immunosuppression possibly due to an overload in fibrinogen and immunoglobulins, have not been reported following infusion of highly purified coagulation factor concentrates. Present state-of-the-art virus inactivation and protein-purification technologies have significantly improved the safety of plasma coagulation factor concentrates.

AB - Plasma-derived coagulation factor concentrates, prepared using traditional manufacturing processes, have transmitted viral diseases, especially AIDS, hepatitis B and hepatitis C to patients. To date, more extensive selection of blood donors, improved screening procedures of each plasma donation for direct and indirect viral markers, and newly developed virucidal procedures, especially pasteurization and solvent-detergent, together with extraction technologies of plasma proteins based on high-resolution chromatographic separations, have diminished considerably the risks of transmitting these pathogenic agents. To ensure safety, each production process must be carefully validated, following a rigorous scientific approach to assess its ability to inactivate or eliminate viruses. In addition, Good Manufacturing Practices must avoid any variation from these validated viral inactivation processes and must eliminate risks of potential downstream contamination of purified plasma fractions following viral inactivation or elimination steps. Other side-effects associated with conventional low-purity preparations, such as acute haemolytic anemia due to contamination by isohaemagglutinins, or immunosuppression possibly due to an overload in fibrinogen and immunoglobulins, have not been reported following infusion of highly purified coagulation factor concentrates. Present state-of-the-art virus inactivation and protein-purification technologies have significantly improved the safety of plasma coagulation factor concentrates.

UR - http://www.scopus.com/inward/record.url?scp=0026784825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026784825&partnerID=8YFLogxK

U2 - 10.1016/S1045-1056(05)80056-9

DO - 10.1016/S1045-1056(05)80056-9

M3 - Review article

VL - 20

SP - 91

EP - 100

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 2

ER -